Phibro Animal Financials
This page shows Phibro Animal (PAHC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 shows a cost-absorption recovery paired with inventory- and debt-funded growth, so cash conversion lagged the income rebound.
The key shift is where profitability improved: gross margin stayed roughly flat, but operating margin rebounded to8.5% from5.2% , which points to better absorption of selling and administrative costs rather than a richer markup on each sale. At the same time, operating cash flow slipped to$80.1M from$87.6M even as earnings recovered, consistent with more cash being tied up in inventory and customer credit.
The balance sheet became more committed to supporting growth: inventory reached
Despite the heavier balance sheet, free cash flow remained positive at
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Phibro Animal's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Phibro Animal has an operating margin of 8.5%, meaning the company retains $9 of operating profit per $100 of revenue. This strong profitability earns a score of 67/100, reflecting efficient cost management and pricing power. This is up from 5.2% the prior year.
Phibro Animal's revenue surged 27.4% year-over-year to $1.3B, reflecting rapid business expansion. This strong growth earns a score of 76/100.
Phibro Animal has elevated debt relative to equity (D/E of 2.15), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 17/100, reflecting increased financial risk.
With a current ratio of 2.76, Phibro Animal holds $2.76 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 74/100.
Phibro Animal has a free cash flow margin of 3.2%, earning a moderate score of 36/100. The company generates positive cash flow after capital investments, but with room for improvement.
Phibro Animal earns a strong 16.9% return on equity (ROE), meaning it generates $17 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 71/100. This is up from 0.9% the prior year.
Phibro Animal scores 2.78, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Phibro Animal passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Phibro Animal generates $1.66 in operating cash flow ($80.1M OCF vs $48.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Phibro Animal earns $3.0 in operating income for every $1 of interest expense ($110.5M vs $37.2M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Phibro Animal generated $1.3B in revenue in fiscal year 2025. This represents an increase of 27.4% from the prior year.
Phibro Animal's EBITDA was $156.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 74.4% from the prior year.
Phibro Animal reported $48.3M in net income in fiscal year 2025. This represents an increase of 1897.7% from the prior year.
Phibro Animal earned $1.19 per diluted share (EPS) in fiscal year 2025. This represents an increase of 1883.3% from the prior year.
Cash & Balance Sheet
Phibro Animal generated $41.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 9.8% from the prior year.
Phibro Animal held $68.0M in cash against $615.4M in long-term debt as of fiscal year 2025.
Phibro Animal paid $0.48 per share in dividends in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Margins & Returns
Phibro Animal's gross margin was 30.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.1 percentage points from the prior year.
Phibro Animal's operating margin was 8.5% in fiscal year 2025, reflecting core business profitability. This is up 3.3 percentage points from the prior year.
Phibro Animal's net profit margin was 3.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 3.5 percentage points from the prior year.
Phibro Animal's ROE was 16.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 16.0 percentage points from the prior year.
Capital Allocation
Phibro Animal invested $23.7M in research and development in fiscal year 2025. This represents a decrease of 18.7% from the prior year.
Phibro Animal invested $38.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 7.1% from the prior year.
PAHC Income Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $383.5M+2.6% | $373.9M+2.8% | $363.9M-3.9% | $378.7M+8.9% | $347.8M+12.5% | $309.3M+18.7% | $260.4M-4.7% | $273.2M |
| Cost of Revenue | $257.9M+6.9% | $241.3M-1.2% | $244.1M-9.1% | $268.7M+10.5% | $243.3M+17.3% | $207.4M+17.2% | $176.9M-4.9% | $186.0M |
| Gross Profit | $125.7M-5.3% | $132.7M+10.7% | $119.8M+8.9% | $110.0M+5.2% | $104.6M+2.6% | $101.9M+22.0% | $83.5M-4.2% | $87.2M |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $81.0M-1.6% | $82.3M+20.1% | $68.5M-10.2% | $76.3M+7.4% | $71.1M-6.9% | $76.3M+16.0% | $65.8M-4.3% | $68.7M |
| Operating Income | $44.7M-11.3% | $50.3M-1.8% | $51.3M+52.0% | $33.7M+0.6% | $33.5M+31.3% | $25.5M+44.3% | $17.7M-3.9% | $18.4M |
| Interest Expense | $10.7M-14.4% | $12.5M-0.5% | $12.5M+38.9% | $9.0M-6.5% | $9.7M-1.3% | $9.8M+11.6% | $8.8M+46.2% | $6.0M |
| Income Tax | $8.3M-7.6% | $9.0M-7.9% | $9.7M+47.1% | $6.6M-24.8% | $8.8M+432.8% | $1.7M-37.5% | $2.6M-53.2% | $5.7M |
| Net Income | $24.0M-12.5% | $27.5M+3.5% | $26.5M+54.0% | $17.2M-17.5% | $20.9M+555.6% | $3.2M-54.3% | $7.0M+827.5% | $752K |
| EPS (Diluted) | $0.59-11.9% | $0.67+3.1% | $0.65 | N/A | $0.51+537.5% | $0.08-52.9% | $0.17 | N/A |
PAHC Balance Sheet
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4B+2.8% | $1.4B+1.4% | $1.4B+1.8% | $1.4B+3.3% | $1.3B+2.5% | $1.3B+33.0% | $966.3M-1.6% | $982.2M |
| Current Assets | $894.1M+3.7% | $862.2M+3.2% | $835.8M+3.1% | $810.6M+4.5% | $776.0M+4.0% | $746.2M+30.7% | $570.8M-5.0% | $601.0M |
| Cash & Equivalents | $54.9M-1.0% | $55.5M-23.8% | $72.8M+7.0% | $68.0M+12.7% | $60.4M-10.0% | $67.1M+29.4% | $51.8M-26.6% | $70.6M |
| Inventory | $539.7M+4.3% | $517.3M+9.7% | $471.8M+6.2% | $444.4M-0.9% | $448.4M+5.0% | $427.2M+56.7% | $272.6M+2.5% | $265.9M |
| Accounts Receivable | $221.5M+2.6% | $215.9M-0.9% | $217.9M-4.4% | $228.0M+15.4% | $197.5M+3.0% | $191.8M+19.3% | $160.8M-5.1% | $169.5M |
| Goodwill | $59.9M+0.1% | $59.8M+0.2% | $59.7M+0.1% | $59.6M+9.3% | $54.6M0.0% | $54.5M-0.1% | $54.6M+0.1% | $54.6M |
| Total Liabilities | $1.1B+0.9% | $1.1B-0.1% | $1.1B-0.1% | $1.1B+2.3% | $1.1B+1.2% | $1.0B+46.8% | $707.8M-2.5% | $725.5M |
| Current Liabilities | $281.9M-0.2% | $282.4M+4.5% | $270.1M-8.0% | $293.5M+10.1% | $266.5M+14.2% | $233.3M+31.9% | $176.9M-13.4% | $204.1M |
| Long-Term Debt | $597.7M-1.0% | $603.6M-1.0% | $609.5M-1.0% | $615.4M-0.6% | $619.2M-0.6% | $622.9M+116.5% | $287.7M+1.9% | $282.3M |
| Total Equity | $361.8M+8.9% | $332.4M+6.6% | $311.7M+9.1% | $285.7M+7.4% | $266.0M+7.8% | $246.8M-4.5% | $258.5M+0.7% | $256.6M |
| Retained Earnings | $336.1M+6.0% | $317.0M+7.7% | $294.4M+7.9% | $272.7M+4.7% | $260.3M+6.6% | $244.3M-0.7% | $246.0M+0.9% | $243.9M |
PAHC Cash Flow Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $16.2M-16.3% | $19.4M+108.0% | $9.3M-56.3% | $21.3M-50.7% | $43.2M+1302.9% | $3.1M-75.6% | $12.6M-55.6% | $28.4M |
| Capital Expenditures | $15.3M+38.0% | $11.1M-19.6% | $13.8M+5.1% | $13.1M+69.7% | $7.7M-1.0% | $7.8M-18.4% | $9.6M-26.7% | $13.1M |
| Free Cash Flow | $890K-89.2% | $8.3M+283.3% | -$4.5M-155.4% | $8.1M-77.0% | $35.4M+846.1% | -$4.7M-256.2% | $3.0M-80.2% | $15.4M |
| Investing Cash Flow | -$16.8M+2.2% | -$17.2M+18.2% | -$21.0M-198.7% | -$7.0M+61.5% | -$18.3M+93.0% | -$260.5M-8789.9% | -$2.9M+67.8% | -$9.1M |
| Financing Cash Flow | -$2.3M+87.9% | -$19.0M-216.2% | $16.3M+310.3% | -$7.8M+75.9% | -$32.2M-111.7% | $276.3M+1046.4% | -$29.2M-1733.9% | $1.8M |
| Dividends Paid | $4.9M+0.1% | $4.9M0.0% | $4.9M0.0% | $4.9M0.0% | $4.9M+0.1% | $4.9M0.0% | $4.9M0.0% | $4.9M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PAHC Financial Ratios
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 32.8%-2.7pp | 35.5%+2.6pp | 32.9%+3.9pp | 29.0%-1.0pp | 30.1%-2.9pp | 32.9%+0.9pp | 32.1%+0.2pp | 31.9% |
| Operating Margin | 11.6%-1.8pp | 13.5%-0.6pp | 14.1%+5.2pp | 8.9%-0.7pp | 9.6%+1.4pp | 8.3%+1.5pp | 6.8%+0.1pp | 6.7% |
| Net Margin | 6.3%-1.1pp | 7.3%+0.1pp | 7.3%+2.7pp | 4.5%-1.4pp | 6.0%+5.0pp | 1.0%-1.7pp | 2.7%+2.4pp | 0.3% |
| Return on Equity | 6.6%-1.6pp | 8.3%-0.2pp | 8.5%+2.5pp | 6.0%-1.8pp | 7.8%+6.6pp | 1.3%-1.4pp | 2.7%+2.4pp | 0.3% |
| Return on Assets | 1.7%-0.3pp | 1.9%+0.0pp | 1.9%+0.6pp | 1.3%-0.3pp | 1.6%+1.3pp | 0.3%-0.5pp | 0.7%+0.6pp | 0.1% |
| Current Ratio | 3.17+0.1 | 3.05-0.0 | 3.09+0.3 | 2.76-0.1 | 2.91-0.3 | 3.20-0.0 | 3.23+0.3 | 2.94 |
| Debt-to-Equity | 1.65-0.2 | 1.82-0.1 | 1.96-0.2 | 2.15-0.2 | 2.33-0.2 | 2.52+1.4 | 1.11+0.0 | 1.10 |
| FCF Margin | 0.2%-2.0pp | 2.2%+3.5pp | -1.2%-3.4pp | 2.1%-8.0pp | 10.2%+11.7pp | -1.5%-2.7pp | 1.2%-4.5pp | 5.6% |
Similar Companies
Frequently Asked Questions
What is Phibro Animal's annual revenue?
Phibro Animal (PAHC) reported $1.3B in total revenue for fiscal year 2025. This represents a 27.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Phibro Animal's revenue growing?
Phibro Animal (PAHC) revenue grew by 27.4% year-over-year, from $1.0B to $1.3B in fiscal year 2025.
Is Phibro Animal profitable?
Yes, Phibro Animal (PAHC) reported a net income of $48.3M in fiscal year 2025, with a net profit margin of 3.7%.
What is Phibro Animal's EBITDA?
Phibro Animal (PAHC) had EBITDA of $156.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Phibro Animal have?
As of fiscal year 2025, Phibro Animal (PAHC) had $68.0M in cash and equivalents against $615.4M in long-term debt.
What is Phibro Animal's gross margin?
Phibro Animal (PAHC) had a gross margin of 30.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Phibro Animal's operating margin?
Phibro Animal (PAHC) had an operating margin of 8.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Phibro Animal's net profit margin?
Phibro Animal (PAHC) had a net profit margin of 3.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Phibro Animal pay dividends?
Yes, Phibro Animal (PAHC) paid $0.48 per share in dividends during fiscal year 2025.
What is Phibro Animal's return on equity (ROE)?
Phibro Animal (PAHC) has a return on equity of 16.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Phibro Animal's free cash flow?
Phibro Animal (PAHC) generated $41.8M in free cash flow during fiscal year 2025. This represents a -9.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Phibro Animal's operating cash flow?
Phibro Animal (PAHC) generated $80.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Phibro Animal's total assets?
Phibro Animal (PAHC) had $1.4B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Phibro Animal's capital expenditures?
Phibro Animal (PAHC) invested $38.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Phibro Animal spend on research and development?
Phibro Animal (PAHC) invested $23.7M in research and development during fiscal year 2025.
What is Phibro Animal's current ratio?
Phibro Animal (PAHC) had a current ratio of 2.76 as of fiscal year 2025, which is generally considered healthy.
What is Phibro Animal's debt-to-equity ratio?
Phibro Animal (PAHC) had a debt-to-equity ratio of 2.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Phibro Animal's return on assets (ROA)?
Phibro Animal (PAHC) had a return on assets of 3.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Phibro Animal's Altman Z-Score?
Phibro Animal (PAHC) has an Altman Z-Score of 2.78, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Phibro Animal's Piotroski F-Score?
Phibro Animal (PAHC) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Phibro Animal's earnings high quality?
Phibro Animal (PAHC) has an earnings quality ratio of 1.66x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Phibro Animal cover its interest payments?
Phibro Animal (PAHC) has an interest coverage ratio of 3.0x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Phibro Animal?
Phibro Animal (PAHC) scores 57 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.